Prevymis (Letermovir)

Prevymis (letermovir) is a CMV DNA terminase complex inhibitor used for:

• Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients aged 6 months and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
• Prophylaxis of CMV disease in adult and pediatric patients aged 12 years and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Recommended Dosage: 

Adult and Pediatric Patients Aged 12 Years and Older and Weighing at least 30 kg Who Are HSCT Recipients or Adult and Pediatric Patients Aged 12 Years and Older and Weighing at least 40 kg Who Are Kidney Transplant Recipients: 

• HSCT: The recommended dosage is 480 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-HSCT. In patients at risk for late CMV infection and disease, treatment with this therapeutic drug may be continued through 200 days post-HSCT.
• Kidney Transplant: The recommended dosage is 480 mg administered once daily orally or as an IV infusion over 1 hour through 200 days post-transplant.  

Pediatric Patients Aged 6 Months to Less than 12 Years or Aged 12 Years and Older and Weighing Less than 30 kg Who Are HSCT Recipients:

• HSCT: Dosing depends on weight and is administered once daily orally or as an IV infusion over 1 hour through 100 days post-HSCT. In patients at risk for late CMV infection and disease, this treatment may be continued through 200 days post-HSCT. 

•  Prevymis can interact with other medicines by increasing side effects or decreasing effectiveness. Always let your doctor know about any medication you are taking, including herbal and over-the-counter medicines, so that the correct monitoring conditions or dosage modifications can be set to avoid potential unsuitable interactions.
• The injectable form of Prevymis 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) contains hydroxypropyl betadex, which could accumulate in patients with kidney issues. Other patients with moderate to severe renal impairment should be monitored closely if given other intravenous (IV) drugs containing the same excipient due to potential toxicity.
• Information regarding Prevymis use in pregnancy is very limited. It’s only advisable to use this medicine if there is a clear indication and the expected benefits outweigh the risks. All women should talk to their healthcare practitioner about the possible impact on the child before commencing the treatment with this medication.
• It is unclear if this therapeutic drug passes into human breast milk. However, to keep infants safe, breastfeeding is not advisable during the course of this medication. Mothers should plan to take off the medicine or stop breastfeeding based on the prescriber’s advice and the clinical need and benefit.
• Letermovir’s influence on fertility is not known. Both men and women of reproductive potential or age should consider relevant contraception while on treatment. Patients looking to conceive should discuss risks and the timing of pregnancy with their healthcare provider (HCP) before starting or continuing treatment.
• Elderly patients may respond differently to this drug because of age-related organ decline. Kidney and liver functions must be evaluated before commencing therapy. In most cases, no modification of dose is deemed necessary, but greater care in monitoring for unwanted effects is necessary for elderly patients.
• There is no need for dose adjustment for Prevymis 240 mg/480 mg tablet users with impaired kidney function. However, for those requiring IV (intravenous) administration, poor kidney function may result in the accumulation of some excipients. Such patients require proper evaluation of kidney function for the selection of the safest route of administration.
• Patients with mild to moderate liver impairment have the right to use Prevymis without changes. Use of Prevymis in patients with severe hepatic impairment has not been studied, so caution is recommended. Active monitoring of liver functions is essential when dealing with patients presenting with known ailments of liver.

What documents are required to import PREVYMIS to India?

PREVYMIS (letermovir) tablets or injections can be imported by patients or government hospitals in the patients’ name only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is PREVYMIS available in India?

PREVYMIS (letermovir tablets or injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Prevymis in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

PREVYMIS can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of PREVYMIS (a prescription medicine) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Prevymis Tablet-Injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source Prevymis (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Prevymis®?

Letermovir is the Generic Name for the trade name drug Prevymis®.

What is the Manufacturer’s Name of Prevymis®?

Prevymis® is manufactured by Merck & Co.

Is Prevymis® approved by the FDA?

No, Prevymis® is approved by the FDA. Date of first Approval: November 8, 2017.

What is the dosage and form of Prevymis® supplied?

Prevymis® is supplied in Tablets: 240 mg; 480 mg for oral administration, and Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) in a single-dose vial for intravenous (IV) use.

What are the most common side effects of Prevymis® Tablets/Injections? 

• The most common side effects of Prevymis® are 
  
• Adult HSCT Patients: nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.
  
• Adult Kidney Transplant Patients: diarrhea.
  
• Pediatric Patients: Adverse events in pediatric patients are similar to adults.

Prices of Prevymis may fluctuate over time because of market dynamics and regulatory changes. To get the most accurate and latest details on the Prevymis Tablets/Injections cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Prevymis® Tablets/Injections be available in SAARC countries? 

Apart from Gulf countries, Prevymis® Tablets/Injections can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Prevymis® in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Prevymis® Tablets/Injections online in India?

Yes, one can buy Prevymis Tablets/Injections online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Prevymis® through legal channels. 

What are the storage conditions of Prevymis® Tablets/Injections?

Prevymis® tablets should be stored at room temperature between 20-25°C. Prevymis® injection vials should be stored in a refrigerator at 2-8°C. Do not freeze. Protect this drug in both forms from light and moisture.